Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and on the tax base of the U.S. and its Territories. Issues related to the taxation of intellectual property income. Issues related to IRC sections 11, 41 and 174, 55, 56A, and 59, 59A, 163(j), 250, 951A.
2026 · 1st Quarter (Jan 1 - Mar 31)
ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION
Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 1, 2026
- Income
- $500,000.00
- Expenses
- Not reported
- Registrant
- THE WASHINGTON TAX & PUBLIC POLICY GROUP
- Filing UUID
- f85b5557-dc26-4b1e-b877-0e174629fd7d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.